Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Summary
This is a multicenter, open-label study to evaluate the long-term safety, tolerability and efficacy of HSK39297. Adult patients with PNH who had previously received and completed HSK39297 study treatment will be included. Eligible subjects can maintain HSK39297 treatment until the end of the study.
Official title: A Multicenter, Open-label Study to Evaluate the Long-term Safety, Tolerability and Efficacy of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria(PNH)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
47
Start Date
2025-01-03
Completion Date
2027-06
Last Updated
2024-12-20
Healthy Volunteers
No
Conditions
Interventions
HSK39297 tablets
HSK39297 tablets until the end of treatment
Locations (1)
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China